Antimetastatic activities and mechanisms of bisdioxopiperazine compounds

Anti-Cancer Agents in Medicinal Chemistry

Volumn 10, Issue 7, 2010, Pages 564-570

  Lu, Da Yong ^a   Lu, Ting Ren ^a  

^a SHANGHAI UNIVERSITY   (China)

Author keywords

Angiogenesis; Antimetastatic drugs; Antineoplastic drugs; Bisdioxopiperazine compounds; Calmodulin; Cell movement; Fibrinogen; Probimane; Razoxane; Sialic acids; Spontaneous metastases

Indexed keywords

ANTIMETASTATIC AGENT; ANTINEOPLASTIC AGENT; BIMOLANE; BISDIOXOPIPERAZINE; CALMODULIN; DNA TOPOISOMERASE (ATP HYDROLYSING); FIBRINOGEN; HOMOHARRINGTONINE; LYCOBETAINE; OXALYSINE; PIPERAZINE DERIVATIVE; PROBIMANE; RAZOXANE; SIALIC ACID; SOBUZOXANE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST TUMOR; CANCER THERAPY; CELL MOTION; DRUG INHIBITION; DRUG MECHANISM; IN VITRO STUDY; IN VIVO STUDY; LUNG CARCINOMA; METASTASIS; METASTASIS INHIBITION; NONHUMAN; SARCOMA;

EID: 78649833522     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152010793498654     Document Type: Article

References (62)

1. Varmus, H. The new era in cancer research. Science, 2006, 312(5777), 1162-1165.
2. Spoon, M.B. The war on cancer. Lancet, 1996, 347(9012), 1377-1381.
3. Jemal, A.; Siegel, R.; Ward, E.; Murray, T.; Xu, J.; Smigal, C.; Thun, M.J. Cancer Statistics, 2006. CA Cancer J. Clin., 2006, 56(2), 106-130.
4. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.P.; Xu J.Q.; Thun, M.J.Cancer statatics, 2009. CA Cancer J. Clin., 2009, 59(4), 225-249.
5. Taraboletti, G., Margosio, B. Antiangiogenic and antivasculartherapy for cancer. Curr. Opin. Pharmacol., 2001, 1(4), 378-384.
6. Folkman, J. New perspectives in clinical oncology from angiogenesisresearch. Eur. J. Cancer, 1996, 32A(14), 2534-2539.
7. Sava, G.; Bergamo, A. Drug control of solid tumour metastases: acritical view. Anticancer Res., 1999, 19(2A), 1117-1124.
8. Lu, D.Y.; Huang, M.; Zhou, J.; Ding J. Recent advances in antimetastaticdrug development. Acta Pharmacol. Sin, 2006, 27(Suppl), 66-67.
9. Verheul, H.M.W.; Pinedo, H.M. Possible molecular mechanismsinvolved in the toxicity of angiogenesis inhibition. Nat. Rev. Cancer, 2007, 7(6), 475-485.
10. Zhang, F.; Zhang, L.; Zhang, B.; Wei, X.; Yang, Y.; Qi, R.Z.; Ying, G.; Zhang, N.; Niu, R. Anexa2 plays a critical role in enhancedinvasiveness of the multidrug resistant human breast cancercells. J. Proteome Res., 2009, 8(11), 5041-5047.
11. Chen, H.; Hao, J.; Wang, L.; Li, Y. Coexpression of invasivemarkers (uPA, CD44) and multiple drug-resistance proteins(MDR1, MRP2) is correlated with epithelial ovarian cancer progression.Br. J. Cancer, 2009, 101(3), 432-440.
12. Dit Faute, M.A.; Laurent, L.; Ploton, D.; Poupon, M.F.; Jardillier, J.C.; Bobichon, H. Distinctive alterations of invasiveness, drug resistanceand cell-cell organization in 3D-cultures of MCF-7, a humanbreast cancer cell lines and its multi-drug resistant variant.Clin. Ex. Metastasis, 2002, 19(2), 161-168.
13. Hahn, W.C. Cancer: surviving on the edge. Cancer Cell, 2004, 6(3), 215-22.
14. Nowell, P.C. The clonal evolution of tumor cell populations. Science(Washington DC), 1976, 194(4260), 23-28.
15. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell, 2000, 100(1), 57-70.
16. Herman, E.H.; Witiak, D.T.; Hellmann, K.; Waradek, V.S. Propertiesof ICRF-159 and related Bis(dioxopiperazine) compounds. Advancesin Pharmacology and Chemotherapy, Garattini, S.; Goldin, A.; Hawking, F.; Kopin, I.J.; Eds. New York: Academy Press, 1982, Vol. 19, pp. 249-290.
17. Hellmann, K.; Burrage K. Control of malignant metastases byICRF-159. Nature, 1969, 224(5216), 273-275.
18. Lu, D.Y; Lu, T.R. Anticancer activities and mechanisms of bisdioxopiperazinecompounds probimane and MST-16. Anti-cancerAgent Med. Chem., 2010, 10(1), 78-91.
19. Ji, R.Y. Probimane. Drugs. Future, 1988, 13(4), 418-419.
20. Okamoto, T.; Nishimura, Y.; Yamada, S.; Yamada, S.; Itoh, T.; Mori, A.; Saheki, K.; Okada, M.; Takatsuka, H.; Wada, H.; Tamura, A.; Fujimori, Y.; Kakishita, E. Long-term administration of oral low-dose topoisomerase II inhibitors, MST-16 and VP- 16, forrefractory or relapsed non-Hodgkin's lymphoma. Acta. Haematol., 2000, 104(2-3), 128-130.
21. Wang, M.Y.; Liu, T.X.; Li, G.T., Zhang, T.M. Effects of bimolaneand probimane on the incorporation of [3H]TdR, [3H]UR and 3H]Leu into Ehrlich ascites carcinoma cells in vitro. Acta. Pharmacol.Sin., 1988, 9(4), 367-369.
22. Zhang, T.M.; Wang, M.Y.; Wang Q.D. Antineoplastic action and toxicity of probimane and its effect on immunologic functions inmice. Acta Pharmacol. Sin., 1987, 8(4), 369-374.
23. Muckter, H.; Frankjus, E.; More, E.; Kollmer, W.E.; Staemmler, M. The influence of cyclic imids on DBA-induced tumors of Sprague-Dawley-rats. Z Krebsforsch, 1967, 69(1), 60-69.
24. Lu, D.Y.; Xu, B.; Ding, J. Anti-tumor effects of two bisdioxopiperazinesagainst two experimental lung cancer models invivo. BMC Pharmacol., 2004, 4, 32.
25. Lu, D.Y.; Wu, F.G.; Shen, Z.M.; Lu, T.R.; Wu, H.Y.;, Che, J.Y.; Xu, B. Different spontaneous pulmonary metastasis inhibitionsagainst Lewis lung carcinoma in mice by Bisdioxopiperazine compoundsof different treatment schedules. Sci. Pharm., 2010, 78(1), 13-20.
26. Poste, G,; Fidler, I.J. The pathogenesis of cancer metastasis. Nature, 1980, 283(5742), 139-146.
27. Fidler, I.J. Critical factors in the biology of human cancer metastasis: Twenty-eight GHA Clowes memorial award lecture. CancerRes., 1990, 50(19), 6130-6138.
28. James, S.E.; Salsbury, A.J. Effect of (±)-1, 2-bis(3, 5-dioxopiperazin-1-yl) propane non tumor blood vessels and its relationshipto the antimetastatic effect in the Lewis lung carcinoma.Cancer Res., 1974, 34(4), 839-842.
29. Lu, D.Y.; Chen, R.T.; Lu, T.R.; Wu, H.Y.; Qu, R.X.; Che, J.Y.; Xu, B. Absorption, distribution and excretion of 14C-probimane inmice bearing Lewis lung carcinoma. Sci. Pharm., 2010, 78(3), 445-450.
30. Lu, D.Y.; Huang, M.; Xu, C.H.; Yang, W.Y.; Hu, C.H.; Lin, L.P.; Tong, L.J.; Li, M.H.; Lu, W.; Zhang, X.W.; Ding, J. Antiproliferative effects, cell cycle G2/M phase arrest and blocking of chromosome segregation by probimane and MST-16 in human tumorcell lines., BMC Pharmacol., 2005, 5, 11.
31. Lu, D.Y.; Huang, M.; Xu, C.H.; Zhu, H.; Xu, B.; Ding, J. Medicinalchemistry of probimane and MST-16: comparison of anticancereffects between bisdioxopiperazines. Med. Chem., 2006, 2 (4), 369-375.
32. Hellmann, K. Dynamics of tumor angiogenesis: effect of razoxaneinducedgrowth rate slowdown. Clin. Exp. Metastasis, 2003, 20(2), 95-102.
33. Salsbury, A.J.; Burrage, K.; Hellmann, K. Histological analysis of the antimetastatic effect of (t)-1, 2-bis(3, 5-dioxopiperazin-1-yl)propane. Cancer Res., 1974, 34(4), 843-849.
34. Braybrooke, J.P.; O'Byrne, K.J.; Propper, D.J.; Blann, A.; Saunders, M.; Dobbs, N.; Han, C.; Woodhull, J.; Mitchell, K.; Crew, J.; Smith, K.; Stephens, R.; Ganesan, T.; Talbot, D.C.; Harris, A.L. Aphase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogatemarkers of angiogenesis. Clin. Cancer Res., 2000, 6(12), 4697-4704.
35. Dvorak, H.F.; Senger, D.R.; Dvorak, A.M. Fibrin as a componentof the tumor stroma: origins and biological significance., CancerMetastasis Rev., 1983, 2(1), 41-73.
36. Costantini, V.; Zacharski, L.R. The role of fibrin in tumor metastasis.Cancer Metastasis Rev., 1992, 11(3), 283-290.
37. Staton, C.A.; Brown, N.J.; Lewis, C.E. The role of fibrinogen and related fragments in tumour angiogenesis and metastasis. ExpertOpin. Biol. Ther., 2003, 3(7), 1105-1120.
38. Lu, D.Y.; Chen, X.L.; Ding, J. Treatment of solid tumors and metastasesby fibrinogen-targeted anticancer drug therapy. Med. Hypotheses, 2007, 68(1), 188-193.
39. Lu, D.Y.; Chi, J.; Lin, L.P.; Huang, M.; Xu, B.; Ding, J. Effect of anticancer drugs on the binding of 125I-fibrinogen to two leukemiacell lines in vitro. J. Int. Med. Res., 2004, 32(4), 488-491.
40. Lu, D.Y.; Chen, X.L.; Cao, J.Y.; Li, Z.; Xue, H.W.; Luo, L.J.; Xu, B. Effects of cancer chemotherapy on the blood fibrinogen concentrationsof cancer patients. J. Int. Med. Res., 2000, 28(5), 313-317.
41. Lu, D.Y.; Chen, X.L.; Huang, M,; Xu, B.; Ding, J. Relationshipbetween blood fibrinogen concentration and pathological featuresof cancer patients: a 139-case clinical study. Online J. Biol. Sci., 2007, 7(1), 8-11.
42. Lu, D.Y.; Cao, J.Y.; Huang, Y.P.; Gong, L.; Chen, X.L.; Chen, E.H.; Xu, B. Comparison of some antineoplastic drugs on inhibitingthrombin catalyzing fibrinogen clotting in vitro. Chin. Med. J.(Eng), 1999, 112(11), 1052-1053.
43. Yogeeswaran, G.; Salk, P.L. Metastatic potential is positively correlatedwith cell surface sialylation of cultured murine tumor celllines. Science (Washington DC), 1981, 212(4502), 1514-1516.
44. Varki, A. Biological roles of oligosaccharides: all of the theoriesare correct. Glycobiology, 1993, 3(2), 97-130.
45. Varki, A. Diversity in the sialic acids. Glycobiology, 1992, 2(1), 25-40.
46. Hakomori, S.I. Tumor malignancy defined by aberrant glycosylationand sphingo(glyco)lipid metabolism. Cancer Res., 1996, 56(23), 5309-5318.
47. Kim, Y.J.; Varki, A. Perspectives on the significance of alteredglycosylation of glycoproteins in cancer. Glycoconjug. J., 1997, 14(5), 569-576.
48. Scanlin, T.F.; Click, M.C. Terminal glycosylation and disease: influence on cancer and cyctic fibrosis. Glycoconjug. J., 2000, 17(7-9), 617-626.
49. Nakamori, S.; Kameyama, M.; Imaoka, S.; Furukawa, H.; Ishikawa, O.; Sasaki, Y.; Kabuto, T.; Iwanaga, T.; Matsushita, Y.; Irimura, T. Increased expression of sialyl LewisX antigen correlateswith poor survival in patients with colorectal carcinoma: clinicopathologicaland immunohistochemical study. Cancer Res., 1993, 53(15), 3632-3637.
50. Kannagi, R. Carbohydrate-mediated cell adhesion involved inhematogenous metastasis of cancer. Glycoconjug. J., 1997, 14(5), 577-583.
51. Higashi, H.; Hirabayashi, Y.; Fukui, Y.; Naiki, M.; Matsumoto, M.; Ueda, S.; Kato, S. Characterization of N-glycolylneuraminic acidcontaining gangliosides as tumor-associated Hanganutziu Deicherantigen in human colon cancer. Cancer Res., 1985, 45(8), 3796-3802.
52. Kawai, T.; Kato, A.; Higashi, H.; Kato, S.; Naiki, M. Quantitativedetermination of N-glycolyl-neuraminic acid expression in humancancerous tissues and avian lymphoma cell lines as a tumorassociatedsialic acid by gas chromatography-mass spectrometry.Cancer Res., 1991, 51(4), 1242-1246.
53. Lu, D.Y,; Xu, J.; Xu, B.; Zhou, A.M. Influence of several antineoplasticdrugs on serum sialic acids of mice bearing tumors. Chin.Biochem. J., 1993, 9(5), 626-30 (Chin).
54. Lu, D.Y.; Liang, G.; Zhang, M.J.; Xu, B. Serum contents of sialicacids in mice bearing different tumors. Chin. Sci. Bull. (Eng)., 1994, 39(14), 1220-1223.
55. Lu, D.Y.; Cao, J.Y. Structural aberration of cellular sialic acids and their functions in cancer. J. Shanghai Univ. (Eng), 2001, 5(2), 164-170.
56. Thejass, P.; Kuttan, G. Antimetastatic activity of Sulforaphane. LifeScience, 2006, 78(26), 3043-3050.
57. Lee, S.J.; Chung, I.M.; Kim, M.Y.; Park, K.D.; Park, W.H.; Moon, H.I. Inhibition of lung metastasis in mice by Oligonol. Phytother.Res., 2009, 23(7), 1043-1046.
58. Lu, D.Y.; Xu, B.; Zhang, X.; Chen, R.T. Distribution of 14C labeledat dioxopiperazine or methyl morphorline group of probimane bywhole body autoradiography. Acta. Pharmacol. Sin., 1993, 14(2), 171-173 (Chin).
59. Lu, D.Y., Chen, X.L., Ding, J. Individualized cancer chemotherapyintegrating drug sensitivity tests, pathological profile analysis and computational coordination-an effective strategy to improveclinical treatment. Med. Hypotheses, 2006, 66(1), 45-51.
60. Etienne-Manneville, S.; Hall, A. Rho GTPases in cell biology.Nature, 2002, 420(6916), 629-635.
61. Nobes, C.D.; Hall, A.; Rho, Rac and Cdc42 regulate the assemblyof multimolecular focal complexes associated with actin stress fibers, lamellipodia and filopodia. Cell, 1995, 81(1), 53-62.
62. Nobes, C.D.; Hall, A. Rho GTPases control polarity, protrusion, and adhesion during cell movement. J. Cell Biol., 1999, 144(6), 1235-1244.